Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 22Myelodysplastic Syndromes 2Targeted Therapy 1Recurrence 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Infections 1Hematologic Neoplasms 1Disease 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

Cyclophosphamide 37fludarabine phosphate 27Whole-Body Irradiation 26Cytarabine 26Mycophenolic Acid 22Methotrexate 20Filgrastim 19Peripheral Blood Stem Cell Transplantation 18Cyclosporine 18fludarabine 17venetoclax 15Busulfan 13Tacrolimus 12Granulocyte Colony-Stimulating Factor 12Cord Blood Stem Cell Transplantation 12Thiotepa 11Antilymphocyte Serum 11Melphalan 10Azacitidine 10Dexamethasone 9Cladribine 9Vincristine 8Specimen Handling 8Radiotherapy 8Mitoxantrone 8Methylprednisolone 8Idarubicin 7Cyclosporins 7Clofarabine 7Hydrocortisone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Biphenotypic, Acute × gilteritinib × Clear all
NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
508 enrolled
MyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡